• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Pharma & Human Health

Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD

December 6, 2021 Microbiome Times

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological conditions, today announced that the first subjects have successfully received their first dose in the company’s global Phase 2b clinical […]

Editor's Choice

Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome

December 2, 2021 Microbiome Times

Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]

Finance

Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy

December 2, 2021 Microbiome Times

Sanofi announced today it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, […]

Finance

Everimmune raises €5m to enter clinical phase in microbiome immuno-oncology

November 30, 2021 Microbiome Times

EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than €5 million (approx. $6M) in a Series A funding from […]

Pharma & Human Health

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

November 19, 2021 Microbiome Times

Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, announced positive results from a Phase 1 study of orally-administered NOV-001 in healthy volunteers. The Phase 1 study demonstrated the ability […]

Pharma & Human Health

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

November 12, 2021 Microbiome Times

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced positive topline results […]

Finance

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

November 10, 2021 Microbiome Times

SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate […]

Finance

ADM to Acquire Deerland Probiotics & Enzymes

November 5, 2021 Microbiome Times

ADM (NYSE: ADM), a global leader in nutrition and agricultural origination and processing, announced a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase U.S.-based Deerland […]

Pharma & Human Health

Probiotics : A Helping Hand Toward a Fitter Life

October 27, 2021 Microbiome Times

For a long time, consumers have associated metabolic health with a healthy weight, but it goes far beyond that. Metabolic health is not about looking good, it is about being healthy, and it involves having […]

Pharma & Human Health

New study characterizes the gut virome

October 25, 2021 Microbiome Times

A new study has added numerous previously uncharacterized viral genomes and genes to the ever-increasing worldwide pool of human gut viromes. The study, published in mSystems, an open-access journal of the American Society for Microbiology, […]

Pharma & Human Health

Solarea Bio Announces Licensing Agreement with ADM

October 20, 2021 Microbiome Times

Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, announced it has signed a technology licensing agreement with global nutrition leader ADM (NYSE: ADM). Solarea Bio has developed […]

Posts navigation

« 1 … 25 26 27 … 76 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter